Develops cancer immunotherapies focusing on the modulation of the tumor microenvironment to enhance anti-tumor immune responses.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, is dedicated to advancing immune-modulating therapies for cancer using its innovative T-win technology platform. At the forefront of its pipeline is IO102-IO103, a promising product candidate targeting key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). Currently, IO102-IO103 is undergoing phase 2 clinical trials for melanoma and phase 1 trials for lung, head and neck, bladder, and melanoma cancers, demonstrating its potential to enhance immune responses against these challenging malignancies.
In addition to IO102-IO103, IO Biotech is developing IO112, a novel therapy containing a specific peptide derived from Arginase 1. This innovative approach aims to activate T cells that recognize epitopes associated with Arginase 1, offering a targeted treatment strategy for various cancers. Through rigorous research and clinical development, IO Biotech seeks to harness the body's immune system to combat cancer effectively.
Founded in 2014 and headquartered in Copenhagen, Denmark, IO Biotech continues to expand its portfolio of immune-oncology candidates. The company's commitment to scientific excellence and therapeutic innovation underscores its mission to improve outcomes for cancer patients worldwide, addressing critical unmet medical needs in oncology with cutting-edge treatments.